VERAライブシグナル | Getagraph.comで利益を最大化

売る 7147 min ago

@ $39.35

発行日: 25 4月 2024 @ 02:31

リターン: 5.57%

前回のシグナル: 4月 24 - 03:31

前回のシグナル: 買う

リターン: -1.87 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:38):

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States...

Stats
本日の出来高	269 760
平均出来高	1.13M
時価総額	2.28B
EPS	$0 ( 2024-03-26 )
次の収益日	( $-0.530 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-18.46
ATR14	$0.119 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Young Joseph R	Sell	5 714	Class A Common Stock
2024-04-03	Grant Sean	Buy	99 828	Class A Common Stock
2024-04-03	Grant Sean	Sell	69 831	Class A Common Stock
2024-04-03	Grant Sean	Sell	10 988	Class A Common Stock
2024-04-03	Grant Sean	Sell	99 828	Stock Option (right to buy)

INSIDER POWER
32.66
Last 98 transactions
Buy: 7 469 518 \| Sell: 2 159 720

ボリューム相関

長: -0.07 (neutral)

短: 0.50 (weak)

Signal:(58.139) Neutral

Vera Therapeutics, Inc. 相関

10 最も正の相関
LCAP	0.928
VTIP	0.912
CYTO	0.907
PAIC	0.896
MTEX	0.892
GAINL	0.889
RMRM	0.886
PROC	0.886
WNW	0.884
OP	0.873

10 最も負の相関
SCR	-0.952
BOCH	-0.924
NETE	-0.919
KIN	-0.914
SHSP	-0.904
IPHA	-0.899
DGLY	-0.898
SRRA	-0.898
THCPU	-0.898
ICON	-0.895

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Vera Therapeutics, Inc. 相関 - 通貨/商品

0.35
( neutral )

0.26
( neutral )

0.00
( neutral )

0.52
( weak )

0.26
( neutral )

0.10
( neutral )

Vera Therapeutics, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$1.86M (0.00 %)
EPS:	$-2.25

FY	2023
収益:	$0
総利益:	$1.86M (0.00 %)
EPS:	$-2.25

FY	2022
収益:	$0
総利益:	$846 000 (0.00 %)
EPS:	$-3.35

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-8.00

Financial Reports:

No articles found.

Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.